(MENAFN- GlobeNewsWire - Nasdaq) LOS ANGELES, Oct. 09, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Jasper Therapeutics, Inc., (“Jasper” or the "Company") (NASDAQ: JSPR) investors of a class action on behalf of investors that bought securities between November 30, 2023 and July 3, 2025, inclusive (the“Class Period”). Jasper investors have until November 18, 2025 to file a lead plaintiff motion.

Investors are encouraged to contact attorney Lesley F. Portnoy , by phone 844-767-8529 or email : ..., to discuss their legal rights, or join the case via . The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to recover their losses.

On July 7, 2025, Jasper issued a press release“reporting updated data from Company's BEACON Phase 1b/2a study of subcutaneous briquilimab in adult participants with CSU and providing an update on the program.” The press release stated that“[r]esults from the 240mg Q8W and the 240mg followed by 180mg Q8W dose cohorts appear to be confounded by an issue with one drug product lot used in those cohorts, with 10 of the 13 patients dosed with drug from the lot in question. The Company is investigating the drug product lot in question and expects to have the results of that investigation in the coming weeks.” On this news, Jasper's stock price fell $3.73 per share, or 55.1%, to close at $3.04 per share on July 7, 2025.

The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing. The Firm's founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA, NY and TX Bar
...
310-692-8883

Attorney Advertising

MENAFN09102025004107003653ID1110175609